This may be attributed to the high heterogeneity of cancer mutations and their distinct pathogenic mechanisms, which often involve mutations in tumor suppressor genes (e.g., TP53 and RB1) and changes in the tumor microenvironment53,54. This evidence concerns the gene TP53 and cancer.